Framingham Genomics Medicine, a company founded with $21 million in venture capital and led in part by Fred Ledley, former CEO and president of Variagenics, plans to close its doors. Formed to organize data from the 52-year-old Framingham Heart Study, the company was forced to disband after Boston University and the National Heart, Lung, and Blood Institute denied it access to the data.
This Heart’s Not for Sale
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.